GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Science Inc (XKRX:343090) » Definitions » Additional Paid-In Capital

HLB Science (XKRX:343090) Additional Paid-In Capital : ₩0.00 Mil(As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is HLB Science Additional Paid-In Capital?


HLB Science's annual additional paid-in capital increased from . 20 (₩0.00 Mil) to Dec. 2022 (₩9,378.63 Mil) and increased from Dec. 2022 (₩9,378.63 Mil) to Dec. 2023 (₩16,663.65 Mil).


HLB Science Additional Paid-In Capital Historical Data

The historical data trend for HLB Science's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Science Additional Paid-In Capital Chart

HLB Science Annual Data
Trend Dec22 Dec23
Additional Paid-In Capital
9,378.63 16,663.65

HLB Science Quarterly Data
Additional Paid-In Capital

HLB Science Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

HLB Science Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of HLB Science's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Science (XKRX:343090) Business Description

Traded in Other Exchanges
N/A
Address
66, Achasan-ro, 6th Floor, Seongdong-gu, Seoul, KOR
HLB Science Inc develops biological new drugs to treat infectious diseases. Its product pipelines includes DD-S052P, DD-A279, and DD-A514.

HLB Science (XKRX:343090) Headlines

No Headlines